LOX and breast cancer: We could detect, that reduced CTGF in mesenchymal transformed breast cancer cells suppressed expression of TGFBI (Fig. 5A; TGFBI CTGF-: 0.6474 ± 0.1107 FC vs. TGFBI control; P = 0.0052; n = 6) and LOX (Fig. 5A; LOX CTGF-: 0.7933 ± 0.043 FC vs. LOX control; P = 0.0088; n = 3), and increased expression of CD44 (Fig. 5A; CD44 CTGF-:1.21 ± 0.045 FC vs. CD44 control; P = 0.0096; n = 3), SPARC (Fig. 5A; SPARC CTGF-: 2.083 ± 0.2749 FC vs. SPARC control; P = 0.0169; n = 3) and FN1 (Fig. 5A; FN1 CTGF-: 1.41 ± 0.07234 FC vs. FN1 control; P = 0.0048; n = 3).